Publications by authors named "Princy Sindurakar"
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab (PDR001), dabrafenib and trametinib in 37 patients with BRAF CRC.
View Article and Find Full Text PDFArticle Synopsis
- Researchers found a gene called TBK1 that helps cancer cells avoid being attacked by the immune system.
- By blocking TBK1, they made cancer treatments, like PD-1 blockade, more effective.
- Experiments with real patient tumors showed that targeting TBK1 can help kill cancer cells better when combined with certain immune signals.
Despite successful use, needle-based immunizations have several issues such as the risk of injuries and infections from the reuse of needles and syringes and the low patient compliance due to pain and fear of needles during immunization. In contrast, needle-free immunizations have several advantages including ease of administration, high level of patient compliance and the possibility of mass vaccination. Thus, there is an increasing interest on developing effective needle-free immunizations via cutaneous and mucosal approaches.
View Article and Find Full Text PDF